Your fact-checks will appear here
American pharmaceutical company
President Trump publicly claimed extraordinarily large drug-price reductions — citing figures like “500%, 600%, 1,000%, 1,500%” — during July and August 2025 remarks and in subsequent events; fact‑che...
The Trump administration and its allies pursued a mix of executive actions, private-sector deals and agency directives that lowered some insulin costs for specific groups while leaving statutory caps ...
The Alzheimer’s field is poised for multiple high‑profile Phase III and confirmatory readouts in 2026, with programs ranging from next‑generation anti‑amyloid antibodies to oral small molecules and me...
Available reporting does not identify randomized clinical trials or peer‑reviewed published studies specifically of a product called “lipoless.” Retail listings claim the supplement contains a patente...
No dementia drug developed or publicly tied to Elon Musk has received FDA or EMA approval as of December 2025 in the available reporting. Neuralink — the Musk-associated company most often linked to n...
OpenSecrets and related reporting show that pharmaceutical/health‑product PACs spent about $16.05 million on federal candidates in the 2024 cycle . Multiple outlets compiling OpenSecrets data list top...
Available reporting shows large pharmaceutical companies and the industry trade group PhRMA gave sizable donations to Donald Trump’s 2025 inauguration committee — filings and press reports cite indivi...
Available reporting shows industrywide totals and past recipient lists but no single authoritative list in the provided sources naming “which senators receive the largest campaign donations from pharm...
There is no credible reporting in the provided sources that President Trump “took $100 million from pharma” as a personal payment. The record in these documents shows aggressive White House pressure o...
Compounded tirzepatide availability and pricing in the U.S. are contested: several lay and vendor sites list compounding pharmacies or telehealth clinics offering tirzepatide at prices typically rangi...
OpenSecrets reports Pharmaceuticals/Health Products PACs gave $16,054,355 to federal candidates in 2024 (industry total), and company PACs such as Pfizer and Merck were major players in 2023–24 giving...
Compounded tirzepatide is strongly restricted and no longer a routine path to lower costs after the FDA ended broad enforcement discretion; current reporting says pharmacies may not legally compound t...
NewSelf presents a mixed public record: the company markets compounded tirzepatide programs with licensed prescribers and pharmacies and holds LegitScript certification, yet independent customer revie...
Compounded versions of tirzepatide are not described in the supplied reporting; available sources document FDA approvals only for branded tirzepatide products (Mounjaro for type 2 diabetes and Zepboun...
Bill Gates has made personal investments aimed at Alzheimer’s research totaling about $100 million — a $50 million check to the Dementia Discovery Fund (DDF) and roughly $50 million pledged for start‑...
Available reporting does not show Donald Trump personally investing his own money into pharmaceutical companies; instead, the Trump administration in 2025 pushed a set of deals and threatened tariffs ...
503A and 503B compounding are separate legal pathways with distinct limits that recently converged on tirzepatide after the FDA declared GLP‑1 shortages resolved—503A pharmacies, state‑licensed and pa...
Clinical trials for prescription weight‑loss medicines — notably GLP‑1 and dual/triple agonists — show large, reproducible reductions in body weight in randomized trials, while smaller peptide product...
Compounded tirzepatide has typically cost patients a few hundred dollars per month versus roughly $1,000–$1,400 per month for brand-name Mounjaro or Zepbound, making the typical out-of-pocket gap abou...
Prescribers, pharmacies and patients face a mix of regulatory, civil‑litigation and patient‑safety risks when relying on compounded tirzepatide instead of FDA‑approved products such as Zepbound: the F...